CLAIMS

1. A therapeutic agent for cancer, wherein a tyrosine kinase inhibitor and an IL-12 inducer are used in combination.

2. The therapeutic agent for cancer according to claim 1, wherein the tyrosine kinase inhibitor has a selective targeting action on at least one receptor selected from the group consisting of the following 1) to 7):

1) HER2/neu; 2) HER3; 3) HER4; 4) c-kit; 5) PDGFR; 6) bcr-abl; and 7) EGFR.

3. The therapeutic agent for cancer according to claim 1, wherein the tyrosine kinase inhibitor has an action with EGFR or c-kit selectively targeted.

4. The therapeutic agent for cancer according to any one of claim 1 to 3, wherein the IL-12 inducer is a substance having a β1,3-1,6 glucan structure.

5. The therapeutic agent for cancer according to claim 4, wherein the IL-12 inducer is a yeast-derived ingredient or an ingredient derived from mushroom mycelium that has a β1,3-1,6 glucan structure.

6. The therapeutic agent for cancer according to any one of claim 1 to 5, which is used in no combination with a chemotherapeutic agent for cancer and a radiation therapy.

7. The therapeutic agent for cancer according to any one of claim 1 to 6, which is used in combination with a substance that selectively acts on NKR-P1 of NKT cell to cause activation of NKT cell.

8. The therapeutic agent for cancer according to any one of claim 1 to 7, which is used in combination with a substance having neovascularization inhibiting capabilities.

9. The therapeutic agent for cancer according to any one of claim 1 to 8, wherein a treatment that combines use of a tyrosine kinase inhibitor and an IL-12 inducer is carried out employing either one of the following 1) and 2) as a marker:

1) an NKTP value before administration showing a measurement value of 5% or more;

2) a Th2 value before administration showing a measurement value of 3% or more.

10. The therapeutic agent for cancer according to any one of claim 1 to 9, wherein a Th1/Th2 ratio that shows an increased measurement value after several months of administration of IRESSA in comparison to a value before administration of IRESSA is taken as a marker for continuation of the combined treatment.

11. The therapeutic agent for cancer according to claim 10, wherein an NKTP value before administration shows a measurement value below 5%.

12. The therapeutic agent for cancer according to claim 9, wherein a marker for continuation of the combined treatment is that measurement values of IL-12 and INFγ after several months of administration of IRESSA have not decreased in comparison with measurement values thereof before

administration of IRESSA.

13. The therapeutic agent for cancer according to any one of claim 1 to 12, wherein the therapeutic agent for cancer is a therapeutic agent for pulmonary adenocarcinoma.

14. A therapeutic method for cancer that uses the therapeutic agent for cancer according to any one of claim 1 to 13.